The Current Ratio as of November 2024 (TTM) for Dermata Therapeutics, Inc. (DRMA) is 7.11

According to Dermata Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.11. This represents a change of 53.54% compared to the average of 4.63 of the last 4 quarters.

Dermata Therapeutics, Inc. (DRMA) Historical Current Ratio (quarterly & annually)

How has DRMA Current Ratio performed in the past?

The mean historical Current Ratio of Dermata Therapeutics, Inc. over the last ten years is 4.29. The current 7.11 Current Ratio has changed 16.47% with respect to the historical average. Over the past ten years (40 quarters), DRMA's Current Ratio was at its highest in in the June 2023 quarter at 12.76. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Dermata Therapeutics, Inc. (DRMA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Dermata Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Dermata Therapeutics, Inc. (DRMA) Average Current Ratio

How has DRMA Current Ratio performed in the past?

The current Current Ratio of Dermata Therapeutics, Inc. (DRMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Dermata Therapeutics, Inc. (DRMA) Current Ratio vs. Peers

How is DRMA’s Current Ratio compared to its peers?

Dermata Therapeutics, Inc.’s Current Ratio is less than Zura Bio Limited (10.36), greater than Phio Pharmaceuticals Corp. (6.38), greater than Sonnet BioTherapeutics Holdings, Inc. (1.65), greater than 180 Life Sciences Corp. (0.19), less than Cardio Diagnostics Holdings, Inc. (8.51), greater than Windtree Therapeutics, Inc. (0.23), greater than Ensysce Biosciences, Inc. (3.24), greater than Panbela Therapeutics, Inc. (0.26), greater than Baudax Bio, Inc. (0.07), greater than ZyVersa Therapeutics, Inc. (0.03), greater than Revelation Biosciences, Inc. (1.64), greater than Navidea Biopharmaceuticals, Inc. (0.56), greater than Altamira Therapeutics Ltd. (1.38), greater than Immix Biopharma, Inc. (3.47), greater than Hepion Pharmaceuticals, Inc. (1.30), less than AVROBIO, Inc. (26.17), greater than eFFECTOR Therapeutics, Inc. (1.03),

Build a custom stock screener for Dermata Therapeutics, Inc. (DRMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dermata Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dermata Therapeutics, Inc. (DRMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dermata Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.